Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.
ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' Lupuzor licensing deal
Quick facts: ImmuPharma PLC
Price: 14.7 GBX
Market Cap: £24.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE